| OMEGA |
3,851 patients with a history of acute MI |
Used a low dose of omega-3 (1 gram), short duration (1 year), inappropriate use of olive oil as a placebo, high baseline intake of fish, unexpected low rate of sudden cardiac death and use of aggressive background medical treatment and the study lacked power to show benefit. |
| Alpha Omega |
4,837 patients with a history of MI |
Patients were already receiving antihypertensive, anti-thrombotic, and lipid-modifying therapies. |
| SU.FOL.OM3 trial |
|
Low dose of omega-3 used (380 mg of EPA/DHA). Small power to detect any positive effect of omega-3s, low major vascular cardiovascular disease events were 15% lower than initially expected, insufficient duration and follow-up. Average time to start omega-3s from cardiovascular event was 101 days compared to 16 days in GISSI-P. Higher use of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers at baseline in the placebo vs. the omega-3 group. Higher number of patents with a history of myocardial infarction and current smoker status in the omega-3 group compared to placebo. |
| ORIGIN |
11,119 patients with high risk of cardiovascular disease and impaired glucose tolerance or diabetes |
Low dose of omega-3 (1 gram/day) used and high background intake of omega-3 fatty acids in study participants. |
